ストックスクリーナーアプリを入手
24.76
0.36%
0.09
Pfizer Inc (PFE) 最新ニュース
Pfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study - MSN
What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter - The Motley Fool
Pfizer Hit With More Suits Over Depo-Provera - Law360
Pfizer (PFE) Valuation in Focus as Strong Clinical Results and New Approvals Spark Renewed Investor Optimism - simplywall.st
Why Pfizer’s Headwinds May Already Be In The Price (NYSE:PFE) - Seeking Alpha
IBM Ranks High For Flexible Roles And Training In AI And Cloud Computing - cnynews.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore - Yahoo
HER-2 Negative Breast Cancer Market 2025 Is Booming Worldwide - openPR.com
Heparin Calcium Market Set to Witness Massive Growth by 2032 - openPR.com
What Do Advances in Pfizer’s Vaccine Pipeline Mean for Its 2025 Valuation? - Yahoo Finance
Fact Check Team: Pfizer sued over alleged tumor risk from contraceptive injection - The National Desk
Pfizer's Cancer Data Did Little To Stoke The Stock. Is It A Buy Or A Sell? - Investor's Business Daily
December 5th Options Now Available For Pfizer (PFE) - Nasdaq
Investment Firm Verity & Verity Loads Up With 908,000 Pfizer (PFE) Shares Worth $22.4 Million - The Globe and Mail
ABRYSVO Receives Expanded Public Funding Across Canadian Provinces for 2025-2026 RSV Season - Financial Times
Pfizer Stock (PFE) Shows Golden Cross After YTD Decline: Momentum Shift Imminent? - AskTraders.com
Nifedipine Medication Market is Going to Booming Growth 2025-2032 | Pfizer Inc., Novartis AG, Merck & Co., Inc. - openPR.com
Cancer Drugs Market Is Booming So Rapidly | Pfizer Inc., Novartis AG, Merck & Co., Inc. - openPR.com
Pfizer Inc. - Britannica
PFIZER INC : Buy rating from Jefferies - MarketScreener
You’ve Still Got It: Aging with Agency to Stay on Top of Your Health Year-Round - Pfizer
Bernstein Remains a Hold on Pfizer (PFE) - The Globe and Mail
Cambridge biotech launches with Pfizer deal, and other life sciences news - The Business Journals
Pfizer Canada Announces Health Canada Approval of ABRYSVO® for Adults 18+ - BioSpace
Pfizer's Accord For A Healthier World Program Challenges Stability Study Norms - Bioprocess Online
Does the Recent 3% Gain Signal a Turning Point for Pfizer Shares? - simplywall.st
mRNA Therapeutics and Global Markets to 2030, Profiles of Leading CompaniesModerna, Pfizer, BioNTech, Merck, and SanofiResearchAndMarkets.com - The AI Journal
Pfizer Canada Announces Health Canada Approval of ABRYSVO® for Adults 18+ (2025-10-21) - Seeking Alpha
2 Mega-Dividend Stocks With Yields As High As 7% - The Globe and Mail
Pfizer (PFE) Receives a Hold from Wells Fargo - The Globe and Mail
Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Relay Therapeutics (RLAY) - The Globe and Mail
Pfizer (PFE): Exploring Valuation as Shares Tick Higher Despite Sector Headwinds - Yahoo Finance
Pfizer's Phase 3 Success and GSK's Rollout Expansion Spark Momentum in the Global Malaria Vaccine Market - openPR.com
Lobbying Update: $2,730,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
What analyst consensus implies for Pfizer Inc. (PFE) stockWeekly Profit Report & Capital Efficient Trade Techniques - nchmf.gov.vn
RSI Check: Will Pfizer Inc. (Common Stock) (PFEB) stock deliver stable dividends2025 Analyst Calls & Accurate Entry and Exit Point Alerts - nchmf.gov.vn
How Pfizer Inc. stock performs in volatility spikesJuly 2025 Retail & Technical Pattern Based Buy Signals - nchmf.gov.vn
Pfizer's Q3 Non-Oncology Performance: Here's What to Expect - sharewise.com
Endometriosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma - Barchart.com
Pfizer's (PFE) Crizotinib Shows Promise in Uveal Melanoma Trial - GuruFocus
Pfizer (PFE): Promising Data from VERITAC-2 Trial on Breast Canc - GuruFocus
Pfizer, Inc. (PFE): Investor Outlook Reveals 17.54% Potential Upside Amid Strong Dividend Yield - DirectorsTalk Interviews
PFIZER INC : JP Morgan sticks Neutral - MarketScreener
Rally Mode: What analyst consensus implies for Pfizer Inc. (PFE) stockJuly 2025 PreEarnings & Technical Pattern Based Signals - nchmf.gov.vn
Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study - Nasdaq
Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025 - GuruFocus
2 High-Yield Dividend Stocks Too Cheap to Ignore - Yahoo Finance
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last? - ts2.tech
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Pfizer
Pfizer Co & Astellas announce final overall survival results from Phase 3 Embark study for Xtandi in combination with Leuprolide - MarketScreener
Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Business Wire
Pfizer says Braftovi + Mektovi shows sustained long-term survival in patients with advanced lung cancer - MarketScreener
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer - Business Wire
Pfizer Stock Forecast – PFE Rises to $24.51 as Metsera Buyout and Seagen Synergies Drive 2025 Growth - TradingNEWS
What insider trading reveals about Pfizer Inc. stockWeekly Investment Recap & Reliable Breakout Stock Forecasts - nchmf.gov.vn
How Positive Phase 3 Cancer Drug Results at Pfizer (PFE) Have Changed Its Investment Story - simplywall.st
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer - Pfizer
Will Pfizer Inc. stock benefit from sector rotationMarket Activity Recap & Weekly Watchlist for Hot Stocks - nchmf.gov.vn
Astellas Pharma Inc. and Pfizer Inc. Announces Positive Results from the Pivotal Phase 3 EV-303 Clinical Trial (Also Known as Keynote-905) for PADCEV - MarketScreener
0.17%
0.39%
大文字化:
|
ボリューム (24 時間):